NPS: FDA Approves Updated Labelling For Gattex To Include Long-term Benefits

(RTTNews) - NPS Pharmaceuticals, Inc. (NPSP) Monday said the U.S. Food and Drug Administration, or FDA, has approved the the changes to the labeling on the company's lead product Gattex to indicate the long-term benefits of the injection.

In a 2-year, open-label study study, patients taking Gattex, which is indicated for the treatment of adults with Short Bowel Syndrome, or SBS, who are dependent on parenteral support, for more than two years achieved clinically meaningful reductions in parenteral support requirements.

Thirteen out of eighty-eight patients achieved complete independence, NPS said in a statement.